Tools
Tools
Minihane, Anne Marie 
ORCID: https://orcid.org/0000-0001-9042-4226, Armah, Christopher K., Miles, Elizabeth A., Madden, Jacqueline M., Clark, Allan B. ORCID: https://orcid.org/0000-0003-2965-8941, Caslake, Muriel J., Packard, Chris J., Kofler, Bettina M., Lietz, Georg, Curtis, Peter J. ORCID: https://orcid.org/0000-0001-5211-047X, Mathers, John C., Williams, Christine M. and Calder, Philip C.
(2016)
Consumption of fish oil providing amounts of eicosapentaenoic acid and docosahexaenoic acid that can be obtained from the diet reduces blood pressure in adults with systolic hypertension: A retrospective analysis.
Journal of Nutrition, 146 (3).
pp. 516-523.
ISSN 0022-3166
Preview |
PDF (NUTRITION_2015_220475 Minihane et al revised_V4_final_PURE)
- Accepted Version
Download (640kB) | Preview |
Abstract
BACKGROUND: Although many randomized controlled trials (RCTs) have examined the effects of the n-3 (ω-3) fatty acids eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) on blood pressure (BP) and vascular function, the majority have used doses of EPA+DHA of >3 g/d, which are unlikely to be achieved by dietary manipulation. OBJECTIVE: The objective was to examine, by using a retrospective analysis from a multicenter RCT, the impact of recommended EPA+DHA intakes achievable through diet on systolic and diastolic BPs and microvascular function in adults in the United Kingdom. METHODS: In a double-blind, placebo-controlled RCT, healthy men and women (n = 312) consumed a control oil or fish oil (FO) providing 0.7 or 1.8 g EPA+DHA/d, in random order, each for 8 wk. Fasting BP and microvascular function (using laser Doppler iontophoresis) were assessed and plasma collected for the quantification of markers of vascular function. Participants were retrospectively genotyped for the endothelial nitric oxide synthase (eNOS) rs1799983 variant. RESULTS: No effects of n-3 fatty acid treatment or any treatment × eNOS genotype interactions were evident in the group as a whole for any of the clinical or biochemical outcomes. Assessment of response according to hypertension status at baseline indicated a significant (P = 0.046) FO-induced reduction (mean: 5 mm Hg) in systolic BP, specifically in those with isolated systolic hypertension (n = 31). No dose response was observed. CONCLUSIONS: These findings indicate that in adults with isolated systolic hypertension, daily doses of EPA+DHA as low as 0.7 g show clinically meaningful BP reductions, which, at a population level, could be associated with lower cardiovascular disease risk. Confirmation of findings in an RCT in which participants are prospectively recruited on the basis of BP status is required to draw definite conclusions.
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |